Marker Therapeutics, Inc.

Monthly Archives: August 2014

TapImmune, Inc. Announces $2 Million Registered Direct Offering

…SEATTLE, Aug 11, 2014 (BUSINESS WIRE) — TapImmune, Inc. (the “Company”), (otcqb:TPIV), today announced that it has entered into a definitive agreement with an institutional investor for a registered direct placement of $2,000,000 of common stock at a price of $1.06 per share.

In addition, the Company will issue to the investor warrants to purchase up to 1,886,793 shares of common stock.

Read More

TapImmune’s New Clinical Trial in Advanced Stage Ovarian Cancer Expands the Use of Folate Receptor Alpha Peptide Antigens

…SEATTLE–(BUSINESS WIRE)–TapImmune Inc. (OTCQB:TPIV) is pleased to announce that a new grant funded Phase I clinical study on the safety and Immunogenicity of folate receptor alpha peptide vaccine in patients with advanced stage epithelial ovarian cancer has started at the Mayo Clinic, Rochester, MN. The folate receptor alpha peptides being used in this study are the same ones that are being used in a current Phase I study in breast and ovarian cancer.

Read More